Business Context and Reporting Period
Ultralife Corporation (ULBI) filed a Form 8-K on September 27, 2024, reporting the entry into a material definitive agreement. The filing details the acquisition of Electrochem Solutions, Inc., a Massachusetts corporation, from Greatbatch Ltd., a subsidiary of Integer Holdings Corporation.
Key Financial Metrics
- Acquisition Price: $50 million for all issued and outstanding shares of Electrochem Solutions, Inc.
- Working Capital: The purchase price is subject to customary working capital adjustments at closing.
- Funding Source: The transaction is expected to be funded through borrowings under credit facilities currently being amended with the Company's primary lender.
- Insurance Costs: The cost of the buyer-side representation and warranty insurance policy is being shared equally between Ultralife and the Seller.
- Other Metrics: The filing does not provide specific values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
This filing represents a material change in the Company's corporate structure and asset base through the proposed acquisition of Electrochem Solutions, Inc. No prior comparable period financial data is presented in this specific 8-K filing.
Outlook, Risks, and Contingencies
- Closing Timeline: The Agreement contemplates closing by the end of October 2024.
- Conditions Precedent: Closing is subject to customary terms, including the procurement of a mutually acceptable buyer-side representation and warranty insurance policy.
- Financing Risk: Funding relies on the successful amendment of existing credit facilities with the primary lender.
- Disclosure Limitations: The filing explicitly states that representations and warranties in the agreement are not characterizations of actual facts and may be modified by disclosure schedules or subsequent information.
Investor Verification Checklist
- Verify the successful amendment of credit facilities to ensure the $50 million funding is secured.
- Confirm the final closing date, as the current target is the end of October 2024.
- Review the final working capital adjustment amount at closing.
- Examine the full text of the Stock Purchase Agreement (Exhibit 10.1) for specific covenants and representations.
- Monitor future filings for the impact of this acquisition on Ultralife's consolidated financial statements.